Table 1.

Inhibitory potency^a of 24 primary hits against pseudovirus infection identified in the US FDA-approved drug library screening and their pharmacological target molecules.

Compound	Target	rVSVΔG-GFP/SARS2-S		rVSVΔG-GFP/VSVG
		GFP (%)	Hoechst (%)	GFP (%)	Hoechst (%)
Bazedoxifene acetate	NR3A (ESR)	12.26	88.96	115.01	102.51
Toremifene	NR3A (ESR) IGF1R (CD221)	21.77	101.27	142.24	90.44
Tamoxifen citrate	NR3A (ESR)	16.27	99.67	105.72	97.14
Toremifene citrate	NR3A (ESR) IGF1R (CD221)	8.32	99.98	109.35	98.74
Raloxifene hydrochloride	NR3A (ESR)	9.66	101.70	97.55	103.53
Vandetanib (ZD6474)	VEGFR2 EGFR RET	20.29	104.11	107.38	99.04
AZD-9291 mesylate	EGFR	5.36	98.67	112.06	98.67
Prochlorperazine Maleate	DRD2	16.56	97.05	131.30	93.26
Thioridazine hydrochloride	DRD2	15.80	98.59	118.64	95.38
Fluphenazine hydrochloride	DRD2	19.31	103.35	106.20	100.59
Perphenazine	DRD2	17.90	104.54	113.49	86.64
Trifluoperazine dihydrochloride	DRD2	8.63	107.56	129.52	97.29
Chlorpromazine hydrochloride	HTR2 HRH1 ADRA2 DRD2 CHRM	24.88	98.41	95.70	97.98
Asenapine Maleate	HTR1A HTR2A HTR2C HTR6 HTR7 DRD2	14.81	98.20	150.43	95.98
Sertraline hydrochloride	SLC6A4 (HTT)	15.85	101.27	104.62	97.33
Trimipramine maleate	SLC6A2 (NAT1) SLC6A4 (HTT)	23.16	103.55	90.44	99.90
Nortriptyline hydrochloride	SLC6A2 (NAT1) SLC6A4 (HTT)	17.44	81.23	91.71	76.77
Amoxapine	SLC6A4 (HTT) SLC6A2 (NAT1)	23.68	102.06	116.48	99.31
Paroxetine hydrochloride	SLC6A4 (HTT)	21.00	102.73	112.39	98.03
Clemastine fumarate	HRH1	12.46	106.94	104.53	101.47
Dronedarone hydrochloride	CACNA1-L KCND3 KCNH2 KCNQ1 KCNJ3 KCNJ5 KCNJ11 ADRA1 ADRB1	10.87	99.72	138.68	101.34
Azithromycin dihydrate	50 S ribosomal subunit	18.36	100.22	101.10	101.30
Cinacalcet hydrochloride	CASR	23.68	97.33	131.09	95.94
Imatinib Mesylate (STI571)	BCR-ABL FIP1L1-PDGFRA KIT (CD117)	20.79	96.53	103.15	94.49

^aThe mean value of vehicle-treated cells was set to 100%.